Actar AB - Product Pipeline Review - Q4 2010

Global Markets Direct, November 2010, Pages: 21

Actar AB – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Actar AB - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Actar AB - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Actar AB human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Actar AB with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Actar AB’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Actar AB’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Actar AB in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Actar AB’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Actar AB.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Actar AB and identify potential opportunities in those areas.

List of Tables
List of Figures
Actar AB Snapshot
Actar AB Overview
Key Information
Key Facts
Actar AB – Research and Development Overview
Key Therapeutic Areas
Actar AB – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Actar AB – Pipeline Products Glance
Actar AB–Early Stage Pipeline Products
Discovery Products/Combination Treatment Modalities
Actar AB – Drug Profiles
A3-3
Product Description
Mechanism of Action
R&D Progress
GLI
Product Description
Mechanism of Action
R&D Progress
MYC
Product Description
Mechanism of Action
R&D Progress
PAK-4
Product Description
Mechanism of Action
R&D Progress
Vascular endothelial growth factor (VEGF)
Product Description
Mechanism of Action
R&D Progress
Actar AB – Pipeline Analysis
Actar AB – Pipeline Products by Therapeutic Class
Actar AB Pipeline Products By Target
Actar AB – Pipeline Products by Molecule Type
Actar AB – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• eLEARNING - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• Charter Schools - Global Outlook
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• The Sweden Defense Industry - Competitive Landscape and Strategic Insights to 2017: Market Profile
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• North America – Smart Weapons Markets and Technologies Outlook – 2013-2020
• The Global UAV Payload Market 2012-2022